Growth equity's insurance pitch runs into the capital charge

Insurance investors spend an enormous amount of time thinking about diversification, Stewart Foley said at the top of the Insurance AUM Journal podcast, and not always about the half that matters: diversifying the names in a portfolio is one exercise, while diversifying the sources of return is another. For a general account whose risk already runs to interest rates and credit spreads, growth equity belongs to the second kind, a return that comes from companies performing rather than from the rate curve or a borrower's ability to repay.

His guest was Suzanne Gauron, who joined General Atlantic in 2025 as a managing director and head of capital solutions for growth equity after more than two decades at Goldman Sachs, where she most recently led private equity capital solutions inside Goldman Sachs Asset Management. That unit reported $2.65 trillion in regulatory assets under management as of September 12, ICD's records show, and her new title pairs capital solutions with growth equity, a hint that structuring for institutional balance sheets sits inside the mandate rather than next to it, even if the public record does not spell that out.

Foley frames the asset class tightly, and the tightness matters. His version sits beyond early-stage venture capital hoping to become profitable someday and apart from the leveraged buyout where financial engineering carries part of the return; it is established companies growing quickly with little borrowing on the balance sheet, where the case rests on whether the business performs. For an insurer, that definition steps around the two exposures a general account is least able to add more of: the companies carry light debt, and their results do not hinge on where rates settle.

What it introduces instead is equity risk, and an insurer ought to be exact about what that means: a stake in a growing company pays no contractual coupon, cannot be modeled to a date the way a private placement can, and its mark will move for reasons unrelated to the insurer that owns it. The liabilities are long-dated and rate-sensitive, the assets built against them are credit-heavy, and the incremental dollar of risk in the book is a spread dollar. A growth equity sleeve stands beside that spread exposure rather than shrinking it, without the coupons, calls or collateral that let an insurer schedule a credit. The diversification is real, but it is diversification of the return driver, not of the cash-flow calendar.

That, Foley said, is the portfolio construction conversation the topic creates, and its honest version is a trade rather than a free addition. It is also the sharpest case for the asset class: an insurer whose book runs on spread assets has diversified the names in it without moving the source of return, while growth equity changes the source, and the difficulty of approving it follows from the same property that makes it useful.

The discipline value extends beyond this one sleeve. A general account that reviews each new allocation for the return driver it adds, and asks whether that driver already sits elsewhere in the book, will find that more than one existing line answers the same way. That is an uncomfortable test for an alternatives schedule assembled one asset class at a time, and it suggests growth equity is more likely to be funded out of an existing allocation than from fresh risk budget.

Alternative managers have spent this cycle annexing insurance balance sheets — acquiring, reinsuring or flow-partnering with life insurers to secure permanent capital — and sidecar capital has compounded at five times the pace of the 4% growth in admitted assets, as this publication has argued, because a sidecar lets a manager put the balance sheet at the center of the pitch without owning the whole insurer. Growth equity arrives through a different door: a sidecar absorbs risk the insurer would otherwise carry, while a fund commitment leaves the risk with the insurer and charges for the exposure. A manager asking a life company for a growth equity allocation is asking on terms less favorable than the ones reinsurance has taught insurers to demand, and a general-account CIO who has negotiated sidecar collateral has the vocabulary to notice.

The published conversation never reaches the capital charge, and that is where the allocation will be decided. Foley's questions and Gauron's answers run to asset-class definition and portfolio construction, ending before the General Atlantic overview and leaving ratings treatment, capital treatment and reporting questions unaddressed. The perimeter around them is moving at the same time: the NAIC is widening its capital formula and SVO designation perimeter through RBC preamble changes and narrowed gap lists, a shift from triage to structural text, and an unrated, equity-like, mark-to-market sleeve sits at the edge of it. The reasonable inference, given nothing in the record addresses the point, is that the capital charge on growth equity gets re-underwritten before most insurers make a first allocation.

If the sleeve gets adopted, the path is likely to be incremental. The likeliest course, offered as inference rather than as reporting, is a modest first commitment taken through a separately managed account or alongside a fund rather than as a blind-pool position, with the review coming after the first valuation cycle rather than after the first vintage. That lets a CIO test the capital charge in practice and keep the line small enough that a soft mark does not move the RBC ratio.

The next turn will hinge on language more than performance: the next round of RBC preamble text and the next narrowing of the gap lists will put a number on what an unrated, equity-like sleeve costs an insurer to hold, and that number will decide whether growth equity earns a line in the general account or stays a rounding error on an alternatives schedule. Insurers will keep taking the meetings. Funding depends on a figure the NAIC has not yet published.